Nuvation Bio showcased longer-term Phase 2 data around the next-gen ROS1 inhibitor it hopes will give Pfizer and Bristol Myers Squibb a run for their money.
In a study conducted in China, taletrectinib spurred an overall response rate of 91% among advanced and metastatic non-small cell lung cancer patients with the ROS1 mutation who have never taken a tyrosine kinase inhibitor (TKI), out to a median follow-up of 23.5 months. In a smaller group of patients pretreated with a TKI, the overall response rate was 52% at a median follow-up of 9.7 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.